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ABSTRACT The fungal pathogen Cryptococcus neoformans has several virulence factors, among which the most important is a
polysaccharide capsule. The size of the capsule is variable and can increase significantly during infection. In this work, we inves-
tigated the relationship between capsular enlargement and the cell cycle. Capsule growth occurred primarily during the G1
phase. Real-time visualization of capsule growth demonstrated that this process occurred before the appearance of the bud and
that capsule growth arrested during budding. Benomyl, which arrests the cells in G2/M, inhibited capsule growth, while siroli-
mus (rapamycin) addition, which induces G1 arrest, resulted in cells with larger capsule. Furthermore, we have characterized a
mutant strain that lacks a putative G1/S cyclin. This mutant showed an increased capacity to enlarge the capsule, both in vivo
(using Galleria mellonella as the host model) and in vitro. In the absence of Cln1, there was a significant increase in the produc-
tion of extracellular vesicles. Proteomic assays suggest that in the cln1 mutant strain, there is an upregulation of the glyoxylate
acid cycle. Besides, this cyclin mutant is avirulent at 37°C, which correlates with growth defects at this temperature in rich me-
dium. In addition, the cln1 mutant showed lower intracellular replication rates in murine macrophages. We conclude that cell
cycle regulatory elements are involved in the modulation of the expression of the main virulence factor in C. neoformans.
IMPORTANCE Cryptococcus neoformans is a pathogenic fungus that has significant incidence worldwide. Its main virulence factor
is a polysaccharide capsule that can increase in size during infection. In this work, we demonstrate that this process occurs in a
specific phase of the cell cycle, in particular, in G1. In agreement, mutants that have an abnormal longer G1 phase show larger
capsule sizes. We believe that our findings are relevant because they provide a link between capsule growth, cell cycle progres-
sion, and virulence in C. neoformans that reveals new aspects about the pathogenicity of this fungus. Moreover, our findings
indicate that cell cycle elements could be used as antifungal targets in C. neoformans by affecting both the growth of the cells and
the expression of the main virulence factor of this pathogenic yeast.
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Cryptococcus neoformans is a facultative intracellular fungalpathogen that causes meningitis, primarily in immunocom-
promised patients (1, 2). Its incidence increased significantly in
association with the HIV pandemic, and it is estimated to cause
more than 650,000 deaths per year, mainly in developing areas (3).
The best-characterized virulence factors of C. neoformans are a
polysaccharide capsule (reviewed in reference 4), melanin pro-
duction (5, 6), and the ability to grow at body temperature (7).
During infection, C. neoformans undergoes changes that contrib-
ute to its persistence. These changes include capsule enlargement
and the appearance of titan/giant cells (8–10).
A characteristic feature of the capsule is its ability to enlarge in
response to certain environmental conditions (11–16). This pro-
cess is believed to be essential for yeast survival in the host, because
capsule growth confers protection against host defense mecha-
nisms, including oxidative stress (17). Moreover, capsule enlarge-
ment has been correlated with increased intracranial pressure
during human cryptococcal meningitis (18). Although capsule
enlargement is an early response of the pathogen during infection,
little is known about its regulation and the underlying molecular
mechanisms that regulate this process. Recent articles have high-
lighted the importance of some transcription factors (such as
Ada2, Rim101, and Gat201) in this process (19–21), indicating
that capsule growth occurs through the induction of a gene ex-
pression rearrangement. In addition, the structurally conserved
Pbs2-Hog1 mitogen-activated protein (MAP) kinase cascade con-
trols morphological differentiation and virulence factors in sero-
type A C. neoformans (22).
In this study, we investigated the hypothesis that capsule en-
largement in C. neoformans is coordinated with the cell cycle. This
idea was hypothesized from different pieces of evidence. Under
conditions of capsule growth, there is normally a decrease in the
growth rate of the yeast, which suggests that factors that elongate
some phases of the cell cycle result in capsule enlargement. In
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addition, we hypothesize that capsule enlargement occurs mainly
in G1, prior to the emergence of the bud, because the addition of
more polysaccharide during the S/G2/M phases might interfere
with budding and the subsequent separation of the bud from the
mother cell. Furthermore, several findings from the literature in-
dicate that there is a correlation between capsule size and cell body
size (11, 23), and the fact that cell body growth occurs mainly in G1
suggests capsule growth would occur in the same cell cycle phase.
Cell cycle control has been extensively studied in Saccharomy-
ces cerevisiae (24, 25), Schizosaccharomyces pombe (26), and Usti-
lago maydis (27). Cell cycle progression depends on the activity of
a cyclin-dependent kinase (Cdk1/Cdc28/Cdc2), which remains
low during G1 and increases its kinase activity during the rest of
the phases (28). The transition between G1 and S is regulated by
specific G1/S cyclins (29, 30). However, little is known about the
cell cycle regulation in C. neoformans. This yeast replicates by bud-
ding, and during the exponential phase, budding and DNA syn-
thesis occur simultaneously (31). However, at the end of the ex-
ponential phase, budding is delayed and cells are arrested at G1 or
G2 phases (32, 33).
To test our hypothesis, we have investigated and modulated
cell cycle progression during capsule growth. In addition, we have
investigated capsular phenotypes in a C. neoformans mutant lack-
ing a putative cyclin. Our results indicate that capsule growth is
linked to cell cycle progression and, in particular, to the G1 phase.
Therefore, we conclude that the link between cell cycle elements
and capsule growth reveals new aspects about the biology of this
virulence factor.
RESULTS
Analysis of DNA content during capsule growth. We first inves-
tigated whether capsule growth changed during the cell cycle pro-
gression of C. neoformans. Consistent with our initial hypothesis,
capsule enlargement occurred mainly during the G1 phase, so we
expected that the cells would arrest in this phase after transfer to
capsule-inducing medium. As shown in Fig. 1A, cells grown over-
night at 30°C in Sabouraud medium were mainly in the G2 phase.
However, when cells were transferred to capsule-inducing me-
dium, we observed an arrest in G1 (shown as “n” in Fig. 1A).
Capsule sizes were measured in parallel at the different time
points to confirm capsule enlargement in the capsule-inducing
medium. Capsule growth was already noticeable after 3 h of incu-
bation under these conditions, and the process continued after 6 h
(P  0.05) (Fig. 1B).
Capsule enlargement process is altered in the presence of cell
cycle inhibitors. We studied the effect of cell cycle inhibitors on
capsule growth. We first used sirolimus (rapamycin), which is an
inhibitor of the TOR pathway and produces G1 arrest. Sirolimus
promoted capsule enlargement of C. neoformans in capsule-
inducing medium (Fig. 2A). For both concentrations tested (0.5
and 1 g/ml), the capsule sizes were significantly larger in cells
exposed to sirolimus relative to the control condition (capsule-
inducing medium with dimethyl sulfoxide [DMSO]) (P  0.05).
To ensure that sirolimus was inhibiting cell cycle progression, we
performed growth curve experiments under the same conditions
and observed a significant defect in the growth rate at the concen-
trations used (Fig. 2B).
We also used benomyl, an inhibitor of microtubule polymer-
ization that induces M-phase arrest. Benomyl inhibited capsule
enlargement of C. neoformans under capsule-inducing conditions
(Fig. 2C) (P  0.05). In addition, benomyl inhibited yeast growth
at both concentrations tested (Fig. 2D). To discard the possibility
that inhibition of capsule growth was not a consequence of cell
death induced by the drug, we measured the viability of the cells
after benomyl treatment by propidium iodide (PI) staining. We
found that approximately 80% of the cells were alive after incuba-
tion with benomyl at the highest concentration tested (data not
shown), indicating that lack of capsule growth was not a conse-
quence of cell death.
Capsule growth visualization by time-lapse microscopy. Ac-
cording to our hypothesis, capsule growth should stop or dimin-
ish during budding, so we used time-lapse microscopy to visualize
capsule growth. The capsule, however, is not visible under regular
conditions given its high water content and similar refractive
properties to that of the medium. Different methods have been
described to visualize the capsule by light microscopy, with India
ink negative staining being the easiest and most widely used in the
literature. We tried to induce capsule growth in medium contain-
ing India ink, but we observed that under these conditions, cap-
sular enlargement was impaired (result not shown), suggesting
that the India ink interferes with the process. Another way to
visualize the capsule is based on a phenomenon known as the
capsular “quellung” reaction (34–37), which involves a change in
the capsule’s optical properties (i.e., refraction index) following
binding of specific monoclonal antibodies (MAbs) to the capsular
polysaccharide. The resulting Ab-coated capsule can be readily
visualized using Nomarski microscopy (also known as differential
interference contrast [DIC]). Given that the IgM MAb 13F1 in-
duced a capsular reaction without significantly affecting the me-
chanical properties of the capsule (38), this antibody was used to
visualize capsule enlargement as a function of time (Fig. 3A).
When cells were transferred to capsule-inducing medium, en-
largements of the cell and capsule were observed at 3.6 and 8.8 nm/
min, respectively (Fig. 3B; see Movie S1 in the supplemental ma-
terial). When the capsule reached a certain size (approximately
6 m), the cell cycle progressed with the subsequent appearance of
the bud and a decrease in capsule growth (Fig. 3B). Interestingly,
after budding, the mother cells with enlarged capsule underwent a
new round of cell cycle with no further cell or capsule growth (see
Movie S1).
Identification of G1/S cyclins in C. neoformans. Next, we in-
vestigated capsular phenotypes in mutants affected in cell cycle
regulation. For this purpose, we identified G1/S cyclins in C. neo-
formans by looking for homologues of the corresponding CLN1
gene from Ustilago maydis (39). Since this organism is also a ba-
sidiomycete, we reasoned that the C. neoformans cell cycle pro-
teins were more homologous to this organism than to those from
members of the ascomycetes, such as Saccharomyces cerevisiae,
Schizosaccharomyces pombe, or Candida albicans. After perform-
ing a BLAST comparison using the Cln1p from U. maydis against
the C. neoformans genome database available at the Broad Insti-
tute, we identified the open reading frame (ORF) CNAG_06092,
which was already annotated as a putative cyclin gene. We ob-
tained the corresponding mutant from a library of targeted dis-
ruptants available at the ATCC (20).
We reconstituted the wild-type (wt) gene in this mutant. For
this purpose, the wild-type gene was fused to the Neo marker,
which confers resistance to Geneticin, using fusion PCR (see Ma-
terials and Methods). The DNA construct was integrated into the
genome by biolistic transformation. In this way, we continued this
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study with the wild-type strain (H99), the cyclin mutant, and the
corresponding reconstituted strain.
Capsule enlargement in vitro. We first investigated whether
capsule size was affected in the cyclin mutant. For this purpose, we
measured the total cell size, the cell body size (delimited by the cell
wall), and the capsule size after growth under regular conditions
(Sabouraud liquid medium) or in capsule-inducing medium
(10% Sabouraud medium [pH 7.3]). As shown in Fig. 4, the cln1
FIG 1 Flow cytometry analysis of cell cycle progression during capsule enlargement. (A) Samples were taken for flow cytometry analysis at the time indicated
after PI staining (see Materials and Methods). Micrographs of cells suspended in India ink were taken in parallel. Sab, Sabouraud medium. (B) Capsule sizes at
the different time points.
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mutant had larger cell body size than the wild-type and reconsti-
tuted strains. The mutant had also significantly larger capsule size
than the other two strains, suggesting that, in fact, capsule size was
coordinated with cell cycle progression.
Time-lapse microscopy revealed differences in G1 length and
budding time in the cln1 mutant. G1/S cyclin mutants showed a
delay in the initiation of DNA replication (40), so we investigated
if the mutant also had a delay in the appearance of the bud. For this
purpose, we performed live imaging and measured the time of cell
growth and budding. We focused on nascent daughter cells, not
on mother cells, since the latter cells have already reached the size
that induces cell cycle progression and the G1 phase is almost
absent after the separation of the bud (41, 42). The analysis of
these videos showed that more than 50% of the cells in the mutant
strain population had defects in cell cycle progression. Daughter
cells showed aberrant shapes and remained attached to the mother
cell, and thus, it was difficult to quantify the time required for
these daughter cells to bud again. However, the other 50% of the
daughter cells managed to completely separate from the mother
cells and showed a significant delay in the appearance of the new
bud compared to the wild-type strain (61  3 min versus 98  12
min; P  0.05) (see Movies S2 and S3 in the supplemental mate-
rial).
The cln1 mutant showed increased vesicle production. Cap-
sule synthesis has been related to the secretion of vesicles with
capsular polysaccharide and other components inside (43, 44).
Therefore, we investigated whether cln1 had an enhanced ability
to secrete vesicles during capsule growth. We isolated and esti-
mated the amount of vesicles from the supernatant of the cultures
by using a fluorometric assay (43, 44). Using this approach, we
observed that cln1 produced more extracellular vesicles than the
wt and reconstituted strains (Fig. 5A). In parallel, we quantified
the amount of sterol present in the vesicle preparation using high-
performance thin-layer chromatography (HPTLC) as an inde-
pendent parameter that reflects vesicle secretion. In agreement
with the fluorometric assay, we found that cln1 had higher sterol
content than the wild-type and reconstituted strains (Fig. 5B and
C).
Analysis of differentially accumulated proteins in cln1 dur-
ing capsule enlargement. To investigate the mechanisms by
which the cln1 mutant produces larger capsules relative to the
wild-type strain, we compared the accumulation of proteins in
these two strains during the capsule enlargement process. We per-
formed protein extraction from wt and cln1 cells incubated under
capsule-inducing conditions for 6 h (see Materials and Methods).
The analysis was performed with 3 independent replicates. Pro-
tein extracts were processed by difference gel electrophoresis
(DIGE). A difference of 1.5-fold change in protein accumula-
tion was considered statistically significant (P  0.05). All possible
proteins and their relative abundance were represented in a heat
map (Fig. 6). Thirty possible proteins were automatically
matched. Twenty-six proteins out of 30 could be cut using Im-
ageQuant v 5.1 software (GE Healthcare) after the gel had been
stained with colloidal Coomassie blue (CCB). These 26 proteins
were imported to the Oracle database, and 19 of them were iden-
tified by mass spectrophotometry with a 4800 matrix-assisted la-
ser desorption ionization–tandem time of flight (MALDI-TOF/
TOF) mass spectrometer. Finally, sequences were identified by
comparison to Cryptococcus neoformans database available at the
Broad Institute.
As shown in Table 1, some proteins involved in meiosis and
budding were less abundant in the cln1 mutant than in the wt
strain (H99). However, proteins such as malate synthase (which is
involved in the glyoxylate cycle and allows the yeast to get energy
from fatty acids) and other proteins related to glucose and xylose
metabolism (i.e., transketolase and aldoketolase) were more
abundant in the cln1 mutant than in the wt strain.
FIG 2 Capsule enlargement in the presence of cell cycle inhibitors. Bars show the means  standard deviations (SD) of the capsule sizes measured from cultures
incubated with different concentrations of sirolimus (rapamycin) (A) or benomyl (C). *, P  0.05. (B and D) Growth curves of C. neoformans in capsule-inducing
medium with the different concentrations of sirolimus (B) and benomyl (D). Cultures containing DMSO were used as controls.
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Virulence and capsule variations of the cln1 strain during
G. mellonella infection. Since the cln1 strain showed a
temperature-sensitive growth defect, we tested its potential viru-
lence in Galleria mellonella (Fig. 7A). We chose this model because
virulence can be assessed at different temperatures (45). The cy-
clin mutant strain was completely avirulent at 37°C (P  0.05). In
contrast, at lower temperature, the mutant was as virulent as the
wild-type strain (P  0.05). Interestingly, cln1 yeast cells recov-
ered after 3 days of infection from larvae incubated at 30 and 37°C
had a larger cell and capsular size than the wt strain (Fig. 7B). In all
cases, the cln1::CLN1 strain restored the virulence phenotype.
We also tested the degree of phagocytosis using the G. mello-
nella model. After 2 h of the administration of the yeasts to the
larvae, hemocytes showed reduced phagocytosis of cln1 strain
compared to the wt and cln1::CLN1 strains (1%  0.7% versus
19%  3% and 13%  1%; P  0.05) (Fig. 7C).
Macrophage and C. neoformans interaction. Phagocytosis as-
says were also performed with the macrophage-like cell line RAW
264.7. Cells from the cln1 mutant were less efficiently phagocyto-
sed by murine macrophages than the wt strain (41%  6% versus
88%  2%, respectively). Furthermore, intracellular replication
was determined using time-lapse microscopy. The Cryptococcus
neoformans wt strain was able to replicate within 30 to 40% of
infected macrophages. In contrast, in macrophages infected with
the cln1 mutant, we only observed fungal replication in 10% of
the cases.
DISCUSSION
Our study provides evidence that capsule enlargement in C. neo-
formans is coordinated with the cell cycle. We hypothesized that
C. neoformans enlarges its capsule during G1 phase for the follow-
ing reasons. Several studies have already shown that capsule en-
largement is induced in C. neoformans in low-iron medium (13),
in the presence of CO2 (15), in serum (11), in diluted Sabouraud
medium (12), or in the presence of mannitol (14). Under each of
these conditions, yeast cells grow more slowly—probably because
they spend more time in G1 phase. Furthermore, it is possible that
the addition of capsule during S/G2/M phases could interfere with
the process of budding and daughter cell separation, thus provid-
ing another reason for linking capsule growth to G1 phase of the
FIG 3 Capsule growth visualization by time-lapse microscopy. Capsule enlargement was observed based on the capsular “quellung” reaction produced by the
13F1 MAb. (A) Sequence of frames showing capsule and cell body enlargement. (B) The rate of capsule and cell body growth was determined by linear regression
analysis of lengths as a function of time. The capsule enlargement speed was 8.8 nm/min, and the cell body enlargement speed was 3.6 nm/min. A plateau in
capsule and cell body size is observed following yeast replication (boxed in gray).
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cell cycle. Moreover, it has been observed that during capsule growth,
there is a correlation between the cell body size and capsule size (11,
23), suggesting that these two processes are in fact coordinated.
Using different techniques (flow cytometry and live imaging),
we confirmed the relationship between capsule growth and G1
arrest. Interestingly, we observed that after capsule enlargement
and bud separation, mother cells progressed normally through the
cell cycle (fast appearance of a new bud with a very short G1
phase), with the absence of further capsule growth. This result
suggests that the G1/S checkpoint is controlled, not only by cell
body size but also by capsule size after capsule enlargement stim-
ulation. This regulation might be dependent on the TOR pathway,
since sirolimus, which also causes G1 arrest (46), enhanced cap-
sule growth. In budding yeast, the TOR pathway detects nutrient
conditions and promotes cell growth and proliferation, which is
also connected to cell size (47). Inhibition of the TOR pathway by
sirolimus leads to arrest cryptococcal cells in G1 phase, and thus
cryptococcal cells have more time to enlarge their capsules. These
results were confirmed by using another cell cycle inhibitor, such
as benomyl. This drug has been described to arrest cells in M phase
due to the loss of microtubule function (48). Our results demon-
strate a link between cell cycle and capsule growth, and open a new
perspective to understand the regulation of this process.
We also investigated capsular phenotypes in a mutant that had
a G1/S cyclin disrupted (CLN1) and which was available at the
ATCC. Parallel studies have phenotypically confirmed the role of
this gene as coding for a G1/S cyclin (31). In preliminary experi-
ments, this mutant manifests an elongated G1 phase and exhibited
a larger capsule relative to the wt strain under capsule-inducing
conditions, confirming that capsule growth was coordinated with
the cell cycle. The cln1 mutant produces more extracellular vesi-
cles than wt and reconstituted strains, which confirmed the hyper-
capsular phenotype of cln1, since it is known that transport of
vesicles in C. neoformans is linked to capsule production (44).
FIG 4 Morphogenesis of wt, cln1, and cln1::CLN1 strains from C. neoformans. (A and B) Distribution of total cell size, cell body size, and capsule diameter of
C. neoformans cells grown in Sabouraud medium (A) and in 10% Sabouraud medium buffered at pH 7.3 with 50 mM MOPS (B).
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Besides, the cln1 mutant also manifested a defect in the width
of the neck between the mother and the bud, which was signifi-
cantly narrower in the WT strain than in the cyclin mutant (31).
This finding had been already reported and could also explain the
delay in budding since it restricts the movement of plasma mem-
brane proteins and cell wall material (31). However, our results
should not be interpreted as if any condition that enlarged G1
phase results in capsule growth, since an inducing signal is re-
quired (i.e., mannitol, serum, CO2, or nutrient deprivation). In
this regard, little is known about the stimuli that trigger capsule
induction, and further studies are required to understand the
changes that occur in the cell during capsule growth.
Our initial characterization of the mutant using time-lapse mi-
croscopy demonstrated that the mutant had an elongated G1
phase, supporting its role in the regulation of the transition from
G1 to S phase. In budding yeasts, the G1 phase in the mother cell is
very short because it has already reached the proper size for cell
division. However, the daughter cell of the cln1 mutant exhibits a
longer G1 phase, until it reaches a cell size that triggers the initia-
tion of the cell cycle (Start) (41, 42, 49). Furthermore, we observed
a significant delay in budding in the cln1 mutant strain compared
to wt or reconstituted strains, which is in agreement with previous
findings (50, 51). This phenomenon could imply that cln1 muta-
tion may cause a delay in a later part of the cell cycle, so that buds
grew large before they separate (52, 53). Alternatively, it could
mean that enlarged mother cells require more time to duplicate all
of their cytoplasmic content during budding because of the larger
size of the cells.
Cell cycle and G1 cyclins are also involved in the morphogen-
esis and differentiation of different yeast species, such as Candida
albicans, Saccharomyces cerevisiae, and Ustilago maydis (39, 54,
55). Our results are in agreement with these findings, since capsule
enlargement can be considered in C. neoformans as a morpholog-
ical transition that involves multiple cellular changes, in particu-
lar, induction of changes in gene expression that result in a dra-
matic accumulation of new polysaccharide in the capsule (20, 21,
56–58). Cyclins are a highly conserved family of proteins that are
involved in multiple processes in the cell through regulation of
specific protein kinases. During cell cycle progression, cyclins
bind and regulate the activity of the cyclin-dependent protein ki-
nases (CDKs). There are several cyclins that control different parts
of the cell cycle through activation of appropriate CDK partners
(59). However, it has been reported that these cyclins could be
involved in different signaling pathways, including fungal devel-
opment, toxin metabolism, and pathogenicity (39, 60). Absence of
Cln1 results in a longer G1 phase, suggesting that this protein is
involved in the regulation of this transition. However, full identi-
fication of the biochemical function of this protein will require
further studies to elucidate whether this protein binds to Cdk1 or
to another protein kinase.
Proteomic analysis showed that some proteins related to mei-
osis and budding were in smaller amounts in the cln1 mutant than
in the wt strain. In the cln1 mutant, proteins related to the glyoxy-
late cycle and glucose metabolism were more abundant than in the
wt strain, which suggests that cln1 cells are more metabolically
active. This result is in agreement with the idea that G1 is the phase
the most metabolically active of the cell cycle. Therefore, our re-
sults suggest a model in which factors that elongate G1 allow cells
to stay in G1 for a longer time and thus increase their capsules.
The protein Wos2 was also more abundant in the cln1 mutant
than in the wt strain. This protein was described as a homolog of
P23 in Schizosaccharomyces pombe that is involved in cell cycle
progression, so its expression decreases when cells enter stationary
phase or are grown under nutrient limitation conditions (61).
Besides, different heat shock proteins appeared differently accu-
FIG 5 The cln1 mutant shows increased production of extracellular vesicles.
(A) Comparative analysis of vesicle production based on an indirect sterol-
based vesicle quantification of fractions obtained from the wt, mutant, and
reconstituted C. neoformans strains, using a fluorometric assay kit. Error bars
represent standard deviations of 3 independent experiments. (B) Comparative
analysis of the sterol content in vesicle preparations using HPTLC. An arrow
indicates the migration of an ergosterol standard (Std). The result is represen-
tative of 2 independent analyses showing similar results. (C) Contrast image of
the area highlighted with the arrow in panel B to emphasize the differences in
band intensity among strains.
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mulated. Some of them were more abundant in the cln1 mutant
than in the wt strain, such as the heat shock protein Hsp90, which
is involved in the response to heat shock and is required for the
viability of the cells (62). In contrast, other heat shock proteins
appeared less abundant in the cln1 mutant than in the wt strain,
such as Hsp70, which has been linked to the expression of laccase
in C. neoformans (63).
The cyclin mutant exhibited virulence defects, especially at
37°C, which are related to its reduced growth at this temperature.
Interestingly, yeast cells recovered from infected larvae showed an
enlarged capsule compared to those observed in vitro (45, 64).
This result correlates with the fact that cryptococcal cells can re-
main in the host in a latent state without being eliminated (re-
viewed in reference 65). Cryptococcus neoformans is an intracellu-
lar fungal pathogen, which means it can persist in hosts inside
macrophages (66–70). However, we have observed that the cln1
mutant is poorly phagocytosed by Galleria hemocytes, possibly
because its larger size impairs its internalization by phagocytic
cells, which correlates with a defect in virulence. Furthermore, this
hypothesis was confirmed by the results observed from the in vitro
FIG 6 Relative abundance of proteins accumulated in the cln1 mutant under capsule-inducing conditions. The upper dendrogram shows the relationship
among individual gels, while the left dendrogram shows the relationship among proteins. Hierarchical clustering analysis (HCA) was performed to obtain the
values of abundance of every spot, which were then represented in a heat map. Different red spots show a positive relative abundance (cln1 mutant/H99 ratio),
while different green spots show a negative relative abundance.
TABLE 1 List of proteins identified by mass spectrophotometrya
Spot Protein identification cln1 mutant/H99 ratio (fold change) ORF
1040 Transketolase 3.74 CNAG_07445
617 Heat shock proteín 90 3.59 CNAG_06150
2002 Wos2 (p21) 2.76 CNAG_07558
861 Malate synthase 2.54
2228 Phosphopyruvate hydrogenase 2.37 CNAG_03072
1427 Aldoketoreductase 1.94 CNAG_01257
974 Chaperone 1.92 CNAG_01750
1222 Ornithine carbamyltransferase 1.8 CNAG_02813
1062 Aminotransferase 1.79 CNAG_02853
860 Malate synthase 1.7 CNAG_05653
1149 Adenylsuccinate synthase 1.68 CNAG_02858
2227 Phosphogluconate dehydrogenase 1.67 CNAG_07561
598 Heat shock protein 1.59 CNAG_05199
915 UTP-glucose-1-phosphate uridyltransferase 1.51 CNAG_02748
1133 Methione adenosyltransferase 1.52 CNAG_00418
584 Heat shock protein 70 1.55 CNAG_01727
532 Heat shock protein 1.69 CNAG_06443
1473 Budding-related protein 2.08 CNAG_04194
531 Meiosis-related protein 2.71 CNAG_00995
a The first and second columns indicate the proteins. The third column shows the fold change in accumulation of the protein between wt and cln1 strains. The last column is the
corresponding ORF for each protein when a BLAST protein-protein comparison was performed in the C. neoformans database of the Broad Institute
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interaction between murine macrophages and wt and cln1 mutant
strains of C. neoformans. Besides, the reduced capability of the cln1
mutant to replicate within macrophages could explain its decrease
in virulence. During the interaction between the cln1 mutant and
murine macrophages, extrusion was only observed in one case,
which leads us to think that, finally, macrophages are able to con-
trol the infection and eliminate the phagocytosed yeast cells.
In summary, our results demonstrate a link between cell cycle
and the regulation of the size of the main virulence factor of
C. neoformans. We propose a model for capsule growth in which
capsule induction stimulus is followed by a transient arrest in G1
that induces capsular enlargement until a certain size is reached,
which then triggers the progression of the cell cycle. We have also
demonstrated that the absence of Cln1 results in reduced viru-
lence, so cryptococcal factors that regulate the cell cycle could
offer a good target to develop new antifungal compounds.
MATERIALS AND METHODS
Strains and culture conditions. Cryptococcus neoformans var. grubii strain
H99 (71) and the cln1 mutant strain CNAG_06092, obtained from a col-
lection of mutants deposited at the ATCC by H. D. Madhani (20), were
used in this study. The strains were routinely grown in liquid Sabouraud
medium (Oxoid, Ltd., Basingstoke, Hampshire, England) at 30°C or 37°C
with moderate shaking (150 rpm). To induce capsule growth, the cells
were transferred to 10% Sabouraud medium buffered at pH 7.3 with
50 mM MOPS (morpholinepropanesulfonic acid) buffer (Sigma-Aldrich,
St. Louis, MO) at 30°C or 37°C with shaking (12). Murine macrophage-
like cells (72) were grown in feeding medium, which contains Dulbecco’s
modified Eagle’s medium (Lonza, Verbiers, Belgium) supplemented with
10% heat-inactivated fetal bovine serum (FBS) (HyClone-Perbio), 10%
NCTC medium (Sigma-Aldrich, Steinheim, Germany) and 1% nonessen-
tial amino acids (Sigma-Aldrich, Steinheim, Germany). Macrophages
were regularly maintained at 37°C in a 5% CO2-enriched atmosphere.
Nuclear staining and FACS analysis. Measurement of DNA content
by flow cytometry was performed as described in reference 52 with minor
modifications. Aliquots were taken at different time intervals from 10%
Sabouraud medium in MOPS buffer and pelleted by centrifugation. Cells
were suspended in 70% ethanol and kept overnight at 4°C for fixation.
The cells were washed twice with distilled water and finally suspended in
2 ml of a mixture of 20 mM sodium citrate, 50 mM EDTA, and 0.45 mM
sorbitol (pH 5.5). After 1 h of incubation at 30°C, RNase (Sigma-Aldrich,
St. Louis, MO) was added at a final concentration of 10 g/ml, and the
tubes were kept at 30°C for 2 h.
Propidium iodide was added to a final concentration of 5 g/ml, and
samples were taken to the cytometer. Samples without propidium iodide
were used in parallel as negative controls. Stained cells were observed
under the fluorescence microscope, and DNA content was measured us-
ing a FacsCalibur flow cytometer (BD Biosciences, Woburn, MA). Flow
cytometry data were processed using CellQuest (BD Biosciences) and
FlowJo (Tree Star, Inc., Ashland, OR) software.
Capsule growth in the presence of cell cycle inhibitors. Cryptococcus
neoformans strain H99 cells were grown in 5 ml of Sabouraud medium at
30°C with moderate agitation. Cells were washed and transferred to 10%
Sabouraud medium in MOPS buffered at pH 7.3 containing sirolimus
(Sigma-Aldrich, St. Louis, MO) at different concentrations (0, 0.5, and
1 g/ml), which induces G1 arrest. In addition, benomyl (Sigma-Aldrich,
St. Louis, MO), which causes M arrest, was also tested for its effect on
capsule growth. Cells were grown in Sabouraud liquid medium at 30°C
overnight and then washed and incubated in 10% Sabouraud medium in
MOPS (pH 7.3) containing different benomyl concentrations (0, 60, and
80 g/ml). Cultures were incubated at 30°C overnight, and suspensions of
India ink were photographed and measured as explained above. DMSO
was added to the control cultures (without drugs). In addition, propidium
iodide (5 g/ml) was added to the cells after incubation with the drugs to
verify that any possible effect on capsule growth was not due to lack of
viability. Heat-killed cells (65°C, 1 h) were used as a positive control.
To confirm that the drugs had an effect on the cells, we performed
growth curves in 10% Sabouraud liquid medium buffered in MOPS at
pH 7.3 containing the different concentrations of the drugs mentioned
above in a 96-well plate (Costar, NY) during 18 h at 30°C using an iEMS
spectrophotometer (Thermofisher). The optical density at 540 nm
(OD540) was measured every hour, and graphs were plotted using Graph
Pad Prism 5.
In vivo capsular growth visualization using time-lapse microscopy.
Cells from the H99 strain were grown overnight in 10 ml of Sabouraud
FIG 7 In vivo model of the effect of cln1. (A) Survival curves of G. mellonella infected with 106 cells of C. neoformans strains at 30°C (left) and 37° C (right) (B)
Capsule sizes of yeast cells recovered from G. mellonella after 3 days of infection at 30 and 37°C. (C) Phagocytosis was performed at a 2:1 ratio of yeast cells to
macrophages (see Materials and Methods). Bars show the mean  SD phagocytosis of C. neoformans cells after 2 h at 37°C. *, P 0.05.
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medium at 30°C under constant agitation. The cells were then washed 3
times with phosphate-buffered saline (PBS), and the density was enumer-
ated using a hemocytometer. Approximately 104 cells were placed in a
Lab-Tek chambered coverglass (Thermo, Fisher Scientific, Rochester,
NY) containing 100 l of capsule-inducing medium (10% Sabouraud
medium buffered in 50 mM MOPS) and supplemented with 20 g/ml of
IgM MAb 13F1 (73). The chamber slide was placed in a temperature-
controlled microscope chamber adjusted to 37°C. Image acquisition was
done at 5-min intervals with a 40 differential inference contrast (DIC)
objective in an SP5 confocal inverted microscope equipped with a camera.
Images were processed using Leica Microsystems and ImageJ software.
Capsule and cell body dimensions were determined from time-lapse mi-
croscopy images using Adobe Photoshop. Capsule radial length was cal-
culated by subtracting the length of the cell body from the diameter of the
whole cell, capsule included. Determination of the capsule and cell body
growth rate was done by linear regression of a length versus time plot.
Identification of G1/S cyclins by homology with the corresponding cy-
clin from Ustilago maydis. The Cln1 protein sequence from Ustilago maydis
(39) was used to perform a BLAST comparison against the C. neoformans H99
strain genome deposited at the Broad Institute (http://www.broadinstitute
.org/annotation/genome/cryptococcus_neoformans/MultiHome.html). In
this way, we identified ORF CNAG_06092, which was already annotated
as coding for a putative cyclin. Moreover, this gene has been characterized
as encoding a G1/S cyclin protein (31) and consequently was denominated
CLN1.
Reconstitution of the CnCLN1 gene. The reconstituted strain (cln1::
CLN1) was created by biolistic DNA delivery. Genomic DNA from wild-
type C. neoformans var. grubii containing the full-length CnCLN1 gene
was amplified by PCR using Phusion high-fidelity DNA polymerase
(Finnzymes, Espoo, Finland) using the primers NEOCLN1 (5= GTCATA
GCTGTTTCCTGGAGCAGGTCTCCTCAACGTCTT 3=) and CLN13=3
(5= AAGTATCACCGTCCAGTTCGTG 3=). The neomycin resistance
marker (74) was amplified from the pPzp plasmid (75) using the primers
CLN1MKRf (5= CTTAGCCGTCTCATAACGCGACCCAGTCACGACG
TTGTA 3=) and NEOCLN1r (5= AAGACGTTGAGGAGACCTGCTCCA
GGAAACAGCTATGAC 3=). The C. neoformans gene cassette was created
by fusion PCR (76, 77) using the CLN1MKRf and CLN13=3 primers.
Biolistic transformation was performed as in reference 76 using a Bio-Rad
PDS 1000/He Biolistic PDS machine. Colonies were selected on YPD
plates containing 100 g/ml of Geneticin, and integration of the gene was
confirmed by PCR.
Estimation of G1-phase length by real-time microscopy. Suspen-
sions of C. neoformans strains were prepared in Sabouraud liquid medium
at 104/ml from overnight cultures. Wells from a 96-well plate were coated
with 50 l of a stock solution of MAb 18B7 at a final concentration of
0.2 g/ml and incubated for 1 h at room temperature. Then mAb18B7
was removed, 100 l from the yeast suspension was added, and the mix-
ture was incubated at 30°C under a Leica DMI 4000B microscope. Pho-
tographs were taken every 2 or 3 min using the 20 objective. The videos
generated by the Leica software were exported as AVI documents and
processed with ImageJ software (NIH; http://rsb.info.nih.gov/ij). The G1
phase was calculated by counting the frames from the appearance of the
first daughter cell until the same daughter cell began to bud again.
Analysis of extracellular vesicle production. The wild type, cln1 mu-
tant, and reconstituted strains were grown in 1-liter cultures of capsule-
inducing medium under constant agitation for 2 days at 30°C. Culture
supernatants, containing extracellular vesicles, were cleared by centrifu-
gation at 5,000  g (25 min, 4°C). Supernatants were then collected and
passed through a 0.8-m-pore filter membrane. The filtered volume was
centrifuged at 100,000  g for 1 h at 4°C using a 45 Ti rotor. Vesicle pellets
were washed 3 times with sterile-filtered cold PBS, with the sample cen-
trifuged each time at 100,000  g for 1 h at 4°C.
Vesicle production was assayed by measuring the concentration of
sterols (structural components and markers of fungal extracellular vesi-
cles and vesicle membranes [44]) by a quantitative fluorometric kit (Am-
plex red sterol assay kit; Molecular Probes) and by high-performance
thin-layer chromatography (HPTLC).
For sterol quantification using the Amplex kit, the resulting pellets
were suspended in 500 l of PBS and processed according to the manu-
facturer’s instructions. The sterol concentration was normalized by cul-
ture’s cell density.
For HPTLC, the vesicle pellets were extracted with 3 sample volumes
of methanol-chloroform (1:1). The mixtures were homogenized by son-
ication. The lower phase (chloroform) was recovered, dried, and sus-
pended in methanol for analysis by HPTLC. The volume of methanol used
to resuspend the lipid material was proportional to the cell density of the
cultures. Thirty microliters of the samples was loaded into HPTLC silica
plates (Si 60F254s; LiChrospher, Merck, Germany) and separated using
the mobile-phase hexane-ether-acetic acid (80:40:2 [vol/vol/vol]). Sterol
spots were identified by spraying the plate with a ferric chloride solution
and heating at 100°C for 3 to 5 min.
Proteomics. To investigate the different patterns of protein accumu-
lation between the cln1 mutant and wt strain, we performed proteomics.
Yeast cells were grown in 10 ml of Sabouraud liquid medium overnight at
30°C. Then the cells were transferred to capsule-inducing medium (10%
Sabouraud in 50 mM MOPS [pH 7.3]) at a final cell density of 107 cells/ml.
After 6 h of incubation at 30°C, cultures were centrifuged at 3,500  g for
10 min, and the pelleted cells were suspended in protein lysis buffer (5 mM
EDTA, 1 Complete protease inhibitor cocktail [Roche, Indianapolis,
IN] in TE buffer [10 mM Tris-HCl at pH 8.1, mM EDTA]). Next, two
aliquots of 1 ml were separated in 2-ml tubes, and 425- to 600-m Ø glass
beads (Sigma-Aldrich, St. Louis, MO) were added. Cell rupture was car-
ried in a Fast-Prep for 6 cycles of 20 s with 4-min intervals in ice. Finally,
tubes were centrifuged for 10 min at 4°C, and supernatants were collected
and kept at 4°C until protein determination using the Bradford protein
assay (Bio-Rad, Munich, Germany) was performed.
Protein samples were analyzed at the Proteomics Facility at the UCM-
UPM (a member of the ProteoRed-ISCIII network). Samples were puri-
fied with the 2D-Clean Up cleaning kit (GE Healthcare). Bradford quan-
tification was confirmed by 10% SDS-PAGE, and samples were stained
with colloidal Coomassie blue (CCB).
Next, the 4 replicates of 100 g from each sample (cln1 mutant and
H99) were mixed and loaded in a two-dimensional (2D)-PAGE gel. To
visualize the proteins, gels were stained with CCB and scanned. Half of the
biological replicates were stained with Cy3 and the other half with Cy5.
Then the gels were scanned in a Typhoon Trio fluorescent scanner (GE
Healthcare) using filters corresponding to each fluorochrome (excitation/
emission: Cy3, 532/580; Cy5, 633/670; Cy2, 488/520 nm). Once scanned,
gels were stained with CCB.
Images were cut with ImageQuant v 5.1 software (GE Healthcare) and
imported to the Oracle database. After the automatic matching of the
putative proteins, manual corrections and matching were carried out.
Different statistical analyses were performed, such as principal-
component analysis and cluster analysis, to obtain the final number of
proteins to be identified by mass spectrophotometry in a 4800 MALDI-
TOF/TOF mass spectrometer. The identification of picks was performed
using the NCBI database with taxonomic restriction in yeast.
Galleria mellonella survival experiments. Galleria mellonella larvae
(Alcotan, Valencia, Spain) were infected as described in references 45 and
64. Briefly, larvae were selected to weigh between 0.3 and 0.5 g and to be
free of any dark marks. Then the pro-leg area was cleaned with 70%
ethanol using a swab. The larvae were inoculated with 10 l of a yeast
suspension prepared at 108/ml in PBS containing 50 g/ml of ampicillin
by an injection using a 26-gauge needle with Hamilton syringes. The sy-
ringes were prepared by cleaning them with diluted bleach and ethanol.
After injection, caterpillars were incubated in 90-mm plastic petri dishes
(Soria Genlab, SA, Madrid, Spain) at 37 or 30°C, and the number of dead
caterpillars was scored every day. A group of 20 larvae were inoculated
with PBS with 50 g/ml of ampicillin in each experiment to monitor
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killing due to physical injury, and another group of 20 caterpillars without
any manipulation were used in parallel as untreated controls.
Isolation of C. neoformans cells from G. mellonella. To isolate the
yeasts from G. mellonella, larvae were smashed using cell strainers with a
100-m pore size (BD Falcon, Erembodegem, Belgium) and 5-ml syringe
plungers (BD Plastipak, Madrid, Spain) (64). Homogenates were col-
lected in 1 ml of PBS, and samples were washed twice and suspended in
150 l of PBS.
Fungal cells were suspended in India ink (Remel Bactidrop, Lenexa,
KS), observed by microscopy, and photographed using a Leica DMI
3000B microscope. In parallel, pictures of the cryptococcal cells grown
overnight in Sabouraud liquid medium were taken to control for cell size
prior to infection (T  0). Cell and capsule sizes were measured using
Adobe Photoshop 7.0 (San Jose, CA). Total cell size was defined as the
diameter of the complete cell, including the capsule. Capsule size was
calculated as the difference between the diameter of the total cell and the
cell body diameter, defined by the cell wall.
In vivo phagocytosis assays. Yeast cells were grown in liquid Sab-
ouraud medium as described above and stained with Calcofluor white
(Sigma-Aldrich, St. Louis, MO) at 10 g/ml for 30 min at 37°C. After
incubation, cells were washed twice with PBS and suspended at 108 cells/
ml. Larvae were infected with 10 l of the inoculum (106 cells) and incu-
bated at 37°C. After 2 h, hemolymph was collected in microcentrifuge
tubes containing 100 l of PBS and centrifuged at 1,500  g for 3 min.
Pelleted hemocytes were suspended in 200 l of PBS and placed on cov-
erslips for 20 min to allow the cells to adhere. Coverslips were placed on
the slides with Fluoromount G (Southern Biotech), and the number of
hemocytes with internalized C. neoformans cells was enumerated using a
Leica DMI 3000B fluorescence microscope. Phagocytosis was expressed as
the percentage of hemocytes that contained yeast cells. Experiments were
performed on different days in triplicates.
Phagocytosis with murine macrophages and Giemsa staining.
Phagocytosis using the murine macrophage cell line RAW 264.7 and Gi-
emsa staining was done as described in reference 78. Using a Leica DMI
3000B microscope, 5 pictures per well were taken to count the total num-
ber of macrophages and the number of macrophages with intracellular
yeasts. The phagocytosis percentage was calculated as the number of in-
fected macrophages divided by the number of total macrophages multi-
plied per 100.
Live imaging of the interaction between murine macrophages and
C. neoformans. After phagocytosis experiments using RAW 264.7 mac-
rophages, performed as described above, the nonphagocytosed yeasts
were removed by extensive washing with macrophage feeding medium.
The 96-well plate (MatTek, Ashland) was placed under a Leica SP5 con-
focal microscope, and pictures were taken using a 20 objective in a 5%
CO2 environment at 37°C. This motorized microscope allows the taking
pictures of different wells in the same experiment. In that sense, two vid-
eos for the wt strain (H99) and 2 videos for the cln1 mutant were obtained
in parallel. Pictures were taken every 3 min for around 12 h. The videos
generated by the Leica software were exported as AVI documents and
processed with ImageJ software (NIH) (http://rsb.info.nih.gov/ij). The
final videos were generated by merging 8 frames per s, with each frame
taken every 3 min, which means that 1 s from the video is equivalent to
24 min of the experiment.
Statistical analysis. Survival data from G. mellonella experiments were
analyzed by the Kaplan-Meier method using Graph Pad Prism 5 (La Jolla,
CA). Every experiment was repeated three times, and the results were
similar among all experiments. Scatter plot analysis of cell sizes was done
with Graph Pad Prism 5 (La Jolla, CA), and statistical differences were
assessed with a t test. A P value of 0.05 was considered significant. The
t test was also performed to evaluate mean differences among the wt, cln1,
and cln1::CLN1 strains regarding the duration of the G1 phase and the
percentage of phagocytosis.
SUPPLEMENTAL MATERIAL
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